Abstract
The fixed dose combination of sitagliptin 50 mg and metformin 850 mg (Janumet ®), is indicated for the treatment of type 2 diabetes mellitus in addition to diet and exercise to improve glycemic control in patients treated with metformin alone. Methods: We report a 69-year-old man with type 2 diabetes that developed sudden loss of eyebrows and eyelashes about 4 months after the beginning of Janumet®.
Clinical and laboratory findings excluded the presence of systemic or skin diseases able to induce these manifestations, while the Naranjo probability scale documented a possible association between the drug and the adverse drug reaction.Keywords: Adverse drug reaction, metformin, sitagliptin, type 2 diabetes mellitus.
Current Drug Safety
Title:Loss of Eyebrows and Eyelashes During Concomitant Treatment with Sitagliptin and Metformin
Volume: 12 Issue: 1
Author(s): Elena Succurro, Caterina Palleria, Mariafrancesca Ruffo, Raffaele Serra, Franco Arturi and Luca Gallelli
Affiliation:
Keywords: Adverse drug reaction, metformin, sitagliptin, type 2 diabetes mellitus.
Abstract: The fixed dose combination of sitagliptin 50 mg and metformin 850 mg (Janumet ®), is indicated for the treatment of type 2 diabetes mellitus in addition to diet and exercise to improve glycemic control in patients treated with metformin alone. Methods: We report a 69-year-old man with type 2 diabetes that developed sudden loss of eyebrows and eyelashes about 4 months after the beginning of Janumet®.
Clinical and laboratory findings excluded the presence of systemic or skin diseases able to induce these manifestations, while the Naranjo probability scale documented a possible association between the drug and the adverse drug reaction.Export Options
About this article
Cite this article as:
Succurro Elena, Palleria Caterina, Ruffo Mariafrancesca, Serra Raffaele, Arturi Franco and Gallelli Luca, Loss of Eyebrows and Eyelashes During Concomitant Treatment with Sitagliptin and Metformin, Current Drug Safety 2017; 12 (1) . https://dx.doi.org/10.2174/1574886311666161014125536
DOI https://dx.doi.org/10.2174/1574886311666161014125536 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review on Role of the Calcium Sensitive Inotropic Agent, Levosimendan and Its Metabolites
Mini-Reviews in Medicinal Chemistry Future Directions in the Treatment of Neuropathic Pain: A Review on Various Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Proteome and Metabolome Alterations in Heart and Liver Indicate Compromised Energy Production During Sepsis
Protein & Peptide Letters Roles of p38-MAPK in Insulin Resistant Heart: Evidence from Bench to Future Bedside Application
Current Pharmaceutical Design Pharmacology of the Human Saphenous Vein
Current Vascular Pharmacology Prognostic Impact of Red Cell Distribution Width on the Development of Contrast-Induced Nephropathy, Major Adverse Cardiac Events, and Mortality in Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention
Current Cardiology Reviews Heat Shock Proteins in Diabetes and Wound Healing
Current Protein & Peptide Science The Complementary Roles of Imaging and ‘Omics’ for Future Anti-Atherosclerotic Drug Development
Current Pharmaceutical Design Would Polymorphic Variants of Dopamine-2 Receptor Gene (DRD2) and Serotonin Transporter Gene (SERT) be a Common Genetic Risk Factor for Comorbid Drug Abuse and Myocardial Ischemia? A Hypothesis- generating Study
Current Pharmacogenomics and Personalized Medicine Your Father and Grandfather’s Atrial Fibrillation: A Review of the Genetics of the Most Common Pathologic Cardiac Dysrhythmia
Current Genomics New Generation Calcium Channel Blockers in Hypertensive Treatment
Current Hypertension Reviews Vascular Disease: A New Progenitor Biology
Current Vascular Pharmacology DNAzyme Delivery Approaches in Biological Settings
Current Medicinal Chemistry Baroreflex Function: Determinants in Healthy Subjects and Disturbances in Diabetes, Obesity and Metabolic Syndrome
Current Diabetes Reviews Regulation of Endothelial Nitric Oxide Synthase in Pathophysiological Conditions
Cardiovascular & Hematological Disorders-Drug Targets Pulmonary Hypertension and Lung Transplantation
Current Hypertension Reviews Stem Cells as a Novel Tool for Drug Screening and Treatment of Degenerative Diseases
Current Pharmaceutical Design Therapeutic Angiogenesis for Islet Revascularization
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Role of Transforming Growth Factor β1 in the Regulation of Blood Pressure
Current Hypertension Reviews Thromboembolic Events in Patients Treated with Anti-Angiogenic Drugs
Current Vascular Pharmacology